ABBVIE INC. - ABBV STOCK NEWS

AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Nimble Therapeutics for $200 million in cash, with additional potential milestone-based payments. The acquisition includes Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease (IBD), along with other novel oral peptide candidates for autoimmune diseases.

The deal also encompasses Nimble's proprietary peptide synthesis, screening, and optimization platform, which accelerates the discovery and optimization of peptide candidates. The IL23R inhibitor targets a clinically validated therapeutic pathway in autoimmune diseases, particularly affecting psoriasis and IBD pathogenesis through increased inflammation and amplified immune responses.

AbbVie (ABBV) has completed its acquisition of Aliada Therapeutics, strengthening its neuroscience pipeline with ALIA-1758, a potential best-in-class disease-modifying therapy for Alzheimer's disease currently in Phase 1 clinical trials. The acquisition brings two key assets: the anti-pyroglutamate amyloid beta antibody ALIA-1758, and a novel blood-brain barrier (BBB)-crossing technology that enhances delivery of targeted drugs into the central nervous system. This strategic move positions AbbVie to address the growing challenge of Alzheimer's disease, which affects millions globally and is becoming more prevalent with aging populations.

AbbVie (ABBV) announced new results from two ongoing clinical trials of epcoritamab in patients with diffuse large B-cell lymphoma (DLBCL). The Phase 1b/2 EPCORE NHL-2 trial showed 100% overall response rate and 87% complete response rate in untreated high-risk DLBCL patients when combined with R-CHOP therapy. Among complete responders, 83% remained in remission after two years.

The Phase 2 EPCORE NHL-1 trial's three-year follow-up, evaluating epcoritamab monotherapy in relapsed/refractory patients, demonstrated 59% overall response rate and 41% complete response rate. Among complete responders, 52% maintained response at three years, with median complete response duration of 36.1 months.

AbbVie announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating tavapadon as a flexible-dose monotherapy in early Parkinson's disease. The trial met its primary endpoint, showing a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III combined score at week 26 compared to placebo (placebo: -1.2; tavapadon 5-15 mg: -10.3; p-value <0.0001). Additionally, it achieved its key secondary endpoint with a significant improvement in motor aspects of daily living (MDS-UPDRS Part II) at week 26. The safety profile was consistent with prior trials, with the majority of adverse events being mild to moderate. AbbVie is on track to submit a New Drug Application (NDA) for tavapadon to the FDA in 2025.

AbbVie released its latest Emotional Impact Report (EIR) at the 66th ASH Annual Meeting, revealing groundbreaking insights into the mental health impacts of chronic lymphocytic leukemia (CLL) on underrepresented patients. The study, involving 232 participants, shows that Black, Hispanic, and Asian patients face unique emotional challenges throughout their cancer journey.

Key findings indicate that ethnically diverse patients strongly desire culturally tailored support resources (45% Asian, 38% Hispanic, 24% Black) compared to 2% of Caucasian respondents. These groups also report higher concerns about financial challenges (35% Black, 39% Asian, 53% Hispanic vs 18% Caucasian). Less than half of all surveyed patients feel supported by their doctors in managing emotional impact, with particularly low rates among Asian (29%), Black (30%), and Hispanic (38%) patients.

AbbVie (ABBV) announced updated results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating epcoritamab plus lenalidomide + rituximab (R2) in patients with relapsed or refractory follicular lymphoma (FL). The trial showed impressive results with a 96% overall response rate and 87% complete response rate among 111 patients with over two years median follow-up.

At 18 months, an estimated 89% of complete responders maintained their response, and 88% of patients showed no detectable disease in minimal residual disease analysis. The most common treatment-emergent adverse events were neutropenia (62%) and cytokine release syndrome (51%). The FDA recently granted breakthrough therapy designation for this combination therapy.

Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF) announces participation in a live investor webinar focused on Duchenne muscular dystrophy (DMD) on December 4, 2024, at 2:00 pm ET. The webinar will feature key opinion leaders discussing three main topics: new treatment approaches for DMD, patient navigation of clinical trials, and Satellos' novel small molecule approach focusing on muscle regeneration.

Featured speakers include Elijah Stacy, a DMD patient advocate and Founder of Destroy Duchenne, Dr. Michael Rudnicki, Scientific Founder of Satellos and Director of Regenerative Medicine at Ottawa Hospital Research Institute, and Dr. Jordan Dubow, Satellos' CMO. The event will include a Q&A session and is free to attend.

AbbVie (NYSE: ABBV) has announced its participation in Citi's 2024 Global Healthcare Conference scheduled for Tuesday, December 3, 2024. The company will be represented by three executive leaders: Scott T. Reents (CFO), Jeffrey R. Stewart (CCO), and Dr. Roopal Thakkar (EVP of R&D and CSO), who will present at 9:15 a.m. Central time.

The presentation will be accessible via live audio webcast through AbbVie's Investor Relations website, with an archived version available later that day.

Allergan Aesthetics, an AbbVie company, has launched AMI Business Education, offering free online business training courses through the AMI Online platform. The initiative includes seven new e-trainings, each under 30 minutes, designed to help healthcare practitioners enhance their practice management with Allergan Aesthetics products. The curriculum covers key areas including practice success ingredients, goal setting, telephone lead conversion, and patient partnership development. The program aims to support practitioners in balancing clinical excellence with business operations, providing practical tools for sustainable growth and practice management efficiency.